Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 7/20 | 0.43 |
| ▸ | CNR1 | P21554 | 4/20 | 0.43 |
| ▸ | HPGDS | O60760 | 1/20 | 0.41 |
| ▸ | FDPS | P14324 | 2/20 | 0.40 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.39 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | IKBKB | O14920 | 1/20 | 0.32 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.31 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.31 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23772002 | 0.90 | CNR2 (0.40) | CNR2CNR1HPGDSFDPSRPS6KA3 | |
| SCHEMBL23772069 | 0.79 | RPS6KA3 (0.39) | CNR2CNR1HPGDSFDPSRPS6KA3 | |
| SCHEMBL23772022 | 0.79 | NPC1 (0.59) | CNR2CNR1NPC1RAB9A | |
| SCHEMBL23772067 | 0.77 | BRD4 (0.46) | CNR2CNR1 | |
| SCHEMBL23772010 | 0.72 | CNR2 (0.41) | CNR2CNR1 | |
| SCHEMBL23772066 | 0.72 | ALDH1A1 (0.42) | CNR2CNR1POLB | |
| SCHEMBL23772011 | 0.70 | L3MBTL1 (0.39) | CNR2CNR1 | |
| SCHEMBL3894242 | 0.70 | HPGDS (0.50) | HPGDSFDPSRPS6KA3RPS6KA2 | |
| SCHEMBL23771954 | 0.69 | HPGDS (0.44) | HPGDSFDPSRPS6KA3RPS6KA2NPC1 | |
| SCHEMBL10353735 | 0.68 | FDPS (0.50) | HPGDSFDPSRPS6KA3RPS6KA2NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210251991-A1 | SUBSTITUTED 2,2'-BIPYRIMIDINYL COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2021-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210251991-A1 | SUBSTITUTED 2,2'-BIPYRIMIDINYL COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME | HAVCR2, CDV3, HMBS | CNR2 3045/4885CNR1 3699/4885HPGDS 181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.